130 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
Fatigue, additional measures of Hb , hemolysis, patient-reported outcomes, physical activity, iron metabolism, safety, PK/PD 24-week core period Open … of transfusion reduction, safety, PK/PD 48-week core period Open-label extension (up to 5 years) 100 mg BID Placebo BID N = 240 2:1 randomization Key
8-K
EX-99.1
jrs7cfy eo9
24 Feb 22
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
7:40am
8-K
EX-99.1
rqfw 0kywjxoqdsjfl
3 Nov 21
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
7:27am